| Dr Emil Antonio Pastrana Ramirez, MD | |
|
100 Ave Luis Munoz Marin Hima Plaza I, Suite 706, Caguas, PR 00725 | |
| (787) 648-9001 | |
| (787) 903-5130 |
| Full Name | Dr Emil Antonio Pastrana Ramirez |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 18 Years |
| Location | 100 Ave Luis Munoz Marin Hima Plaza I, Caguas, Puerto Rico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710182118 | NPI | - | NPPES |
| Entity Name | Recinto De Ciencias Medicas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720163058 PECOS PAC ID: 3678469962 Enrollment ID: O20040424000410 |
News Archive
The Journal of Biological Chemistry's editors are unveiling this week a number of changes to the journal's publishing policies. They say the changes are in response to the increasingly interdisciplinary nature of biological research and will help the journal better meet the evolving needs of the scientific community.
Genentech, Inc., a wholly owned member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Mood disorders are among the most prevalent mental health issues today. While medication is available, more and more people are turning to complementary and alternative medicine (CAM), including herbal remedies, acupuncture, and meditation to help manage their mood disorders.
Dimerix Bioscience Pty Ltd, a pre-clinical stage product company developing a pipeline of 'best in class' lead products with highly specific activity and with reduced risk of off-target effects, today announced that it has entered into a research agreement with Takeda Cambridge Limited, a UK based subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company.
Alcon, Inc. reported that global sales rose 14.5 percent to $1.72 billion for the fourth quarter of 2009, or an 8.5 percent increase excluding the impact of foreign exchange fluctuations. Reported net earnings for the fourth quarter of 2009 grew 8.0 percent to $458 million, or $1.51 per diluted share.
› Verified 7 days ago
| Entity Name | Hospital Espanol Auxilio Mutuo De Puerto Rico, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376561522 PECOS PAC ID: 4183602832 Enrollment ID: O20040807000223 |
News Archive
The Journal of Biological Chemistry's editors are unveiling this week a number of changes to the journal's publishing policies. They say the changes are in response to the increasingly interdisciplinary nature of biological research and will help the journal better meet the evolving needs of the scientific community.
Genentech, Inc., a wholly owned member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Mood disorders are among the most prevalent mental health issues today. While medication is available, more and more people are turning to complementary and alternative medicine (CAM), including herbal remedies, acupuncture, and meditation to help manage their mood disorders.
Dimerix Bioscience Pty Ltd, a pre-clinical stage product company developing a pipeline of 'best in class' lead products with highly specific activity and with reduced risk of off-target effects, today announced that it has entered into a research agreement with Takeda Cambridge Limited, a UK based subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company.
Alcon, Inc. reported that global sales rose 14.5 percent to $1.72 billion for the fourth quarter of 2009, or an 8.5 percent increase excluding the impact of foreign exchange fluctuations. Reported net earnings for the fourth quarter of 2009 grew 8.0 percent to $458 million, or $1.51 per diluted share.
› Verified 7 days ago
| Entity Name | Centro Medico Del Turabo Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710107883 PECOS PAC ID: 9335051952 Enrollment ID: O20080212000105 |
News Archive
The Journal of Biological Chemistry's editors are unveiling this week a number of changes to the journal's publishing policies. They say the changes are in response to the increasingly interdisciplinary nature of biological research and will help the journal better meet the evolving needs of the scientific community.
Genentech, Inc., a wholly owned member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Mood disorders are among the most prevalent mental health issues today. While medication is available, more and more people are turning to complementary and alternative medicine (CAM), including herbal remedies, acupuncture, and meditation to help manage their mood disorders.
Dimerix Bioscience Pty Ltd, a pre-clinical stage product company developing a pipeline of 'best in class' lead products with highly specific activity and with reduced risk of off-target effects, today announced that it has entered into a research agreement with Takeda Cambridge Limited, a UK based subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company.
Alcon, Inc. reported that global sales rose 14.5 percent to $1.72 billion for the fourth quarter of 2009, or an 8.5 percent increase excluding the impact of foreign exchange fluctuations. Reported net earnings for the fourth quarter of 2009 grew 8.0 percent to $458 million, or $1.51 per diluted share.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Emil Antonio Pastrana Ramirez, MD 7 Calle Orquidea, San Juan, PR 00927-6726 Ph: (787) 436-9521 | Dr Emil Antonio Pastrana Ramirez, MD 100 Ave Luis Munoz Marin Hima Plaza I, Suite 706, Caguas, PR 00725 Ph: (787) 648-9001 |
News Archive
The Journal of Biological Chemistry's editors are unveiling this week a number of changes to the journal's publishing policies. They say the changes are in response to the increasingly interdisciplinary nature of biological research and will help the journal better meet the evolving needs of the scientific community.
Genentech, Inc., a wholly owned member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Mood disorders are among the most prevalent mental health issues today. While medication is available, more and more people are turning to complementary and alternative medicine (CAM), including herbal remedies, acupuncture, and meditation to help manage their mood disorders.
Dimerix Bioscience Pty Ltd, a pre-clinical stage product company developing a pipeline of 'best in class' lead products with highly specific activity and with reduced risk of off-target effects, today announced that it has entered into a research agreement with Takeda Cambridge Limited, a UK based subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company.
Alcon, Inc. reported that global sales rose 14.5 percent to $1.72 billion for the fourth quarter of 2009, or an 8.5 percent increase excluding the impact of foreign exchange fluctuations. Reported net earnings for the fourth quarter of 2009 grew 8.0 percent to $458 million, or $1.51 per diluted share.
› Verified 7 days ago
Luis Jose Almodovar Fabregas, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Ave L Munoz Marin Ste 706, Caguas, PR 00725 Phone: 787-653-2217 | |
Dr. Yadira Dacosta, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: Hospital Hima Caguas, Ave Luis Munoz Marin Urb Mariolga, Caguas, PR 00726 Phone: 787-653-3434 | |
Dr. Ivan J Sosa Gonzalez, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Ave Luis Munoz Marin, Caguas, PR 00725 Phone: 787-653-3434 Fax: 787-961-1913 |